Stockscreener 앱 받기
3.62
3.43%
0.12
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Iovance Biotherapeutics (IOVA) Nears Profitability with 2027 Projection - GuruFocus
Iovance Biotherapeutics (IOVA) to Announce Q1 2025 Financial Results - GuruFocus
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 | IOVA Stock News - GuruFocus
Iovance Biotherapeutics to Host First Quarter 2025 - GlobeNewswire
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future - Yahoo Finance
Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Expected To Breakeven In The Medium-Term - simplywall.st
2 Beaten-Down Stocks With Incredible Upside Potential - Yahoo
Press Release Distribution & PR Platform - ACCESS Newswire
Iovance Biotherapeutics to Present Pre-Clinical and Five-Year Outcomes Data at 2025 AACR and ASCO Annual Meetings - Nasdaq
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses - GlobeNewswire
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year. - MSN
Iovance Biotherapeutics: Only For The Brave (NASDAQ:IOVA) - Seeking Alpha
Commit To Buy Iovance Biotherapeutics At $2.50, Earn 35.1% Annualized Using Options - Nasdaq
Iovance Biotherapeutics (IOVA) Projects Strong Growth with FDA-A - GuruFocus
This Biotech Stock Could Be the Best Investment of the Decade - Yahoo
Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts? - Insider Monkey
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ L - GuruFocus
11 Most Promising Penny Stocks According to Analysts - Insider Monkey
Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Barclays Adjusts Iovance Biotherapeutics (IOVA) Price Target Ami - GuruFocus
Is Iovance Biotherapeutics a Millionaire-Maker? - MSN
Barclays cuts Iovance Biotherapeutics target to $5, keeps rating By Investing.com - Investing.com Canada
Iovance Biotherapeutics (IOVA) Eyes Revenue Growth with TIL Ther - GuruFocus
TILs’ Tomorrow Bringing More Cancers Under Immune Control - Genetic Engineering and Biotechnology News
Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Trading (IOVA) With Integrated Risk Controls - news.stocktradersdaily.com
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction - Yahoo Finance
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail
Iovance: Less And Less Likely To Reap Reward From Its Pioneering Work (NASDAQ:IOVA) - Seeking Alpha
Institutional Investors May Adopt Severe Steps After Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Latest 8.3% Drop Adds to a Year Losses - 富途牛牛
Tumor-Infiltrating Lymphocytes Treatment Market Size in 7MM - openPR.com
Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally - Yahoo Finance
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month - Benzinga
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey
0.35%
0.36%
자본화:
|
볼륨(24시간):